Top

Journal of Gastroenterology

Published in:

01-05-2013 | Letter to the Editor

Insulin-related biomarkers and their relationship with hepatic fibrosis risk in patients with psoriasis, metabolic syndrome and non-alcoholic fatty liver disease

Author: Tomoyuki Kawada

Published in: Journal of Gastroenterology | Issue 5/2013

Excerpt

To the Editor: …

Campanati A, Ganzetti G, Sario AD, Damiani A, Sandroni L, Rosa L, et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol. 2012 Oct 13. doi:10.1007/s00535-012-0678-9.

Vaccaro O, Masulli M, Cuomo V, Rivellese AA, Uusitupa M, Vessby B, et al. Comparative evaluation of simple indices of insulin resistance. Metabolism. 2004;53(12):1522–6.PubMedCrossRef

Kawada T. Preliminary report: homeostasis model assessment of insulin resistance, an indicator of insulin resistance, is strongly related to serum insulin: practical data presentation and the mathematical basis. Metabolism. 2010;59(7):1044–6.PubMedCrossRef

Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–95.PubMedCrossRef

Martinez-Hervas S, Argente C, Garcia-Jodar J, Priego A, Real JT, Carratala A, et al. Misclassification of subjects with insulin resistance and associated cardiovascular risk factors by homeostasis model assessment index. Utility of a postprandial method based on oral glucose tolerance test. Metabolism. 2011;60(5):740–6.PubMedCrossRef

Title: Insulin-related biomarkers and their relationship with hepatic fibrosis risk in patients with psoriasis, metabolic syndrome and non-alcoholic fatty liver disease
Author: Tomoyuki Kawada
Publication date: 01-05-2013
Publisher: Springer Japan
Published in: Journal of Gastroenterology / Issue 5/2013
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-013-0768-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 5/2013

Esophageal intraluminal baseline impedance is associated with severity of acid reflux and epithelial structural abnormalities in patients with gastroesophageal reflux disease

Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer

Deletion of Nrf2 leads to rapid progression of steatohepatitis in mice fed atherogenic plus high-fat diet

Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors

Adherence to the preventive strategies for nonsteroidal anti-inflammatory drug- or low-dose aspirin-induced gastrointestinal injuries

Association of enhanced activity of indoleamine 2,3-dioxygenase in dendritic cells with the induction of regulatory T cells in chronic hepatitis C infection

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials